Altair Nanotechnogies Inc.
of Reno said last week it licensed its RenaZorb technology for the treatment of kidney disease to Spectrum Pharmaceuticals Inc.
Spectrum will pay Altair 100,000 shares of restricted Spectrum stock (the stock was trading at about $6 last week) and make an equity investment of $200,000 for 38,314 shares of Altair common stock.
Other financial details weren't disclosed.
Publicly held Altair has said RenaZorb has the potential to treat high phosphorous levels in the blood of kidney patients.
